Raloxifene reduces atherosclerosis: Studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits

Clinical Endocrinology

Volumn 52, Issue 2, 2000, Pages 225-233

  Bjarnason, Nina Hannover ^a,c   Haarbo, Jens ^a   Byrjalsen, Inger ^a   Kauffman, Raymond F ^b   Knadler, Mary Pat ^b   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b ELI LILLY AND COMPANY   (United States)

^c CCBR   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR MODULATOR; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL INTAKE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; LIPID BLOOD LEVEL; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RABBIT;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, DIETARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; ORGAN SIZE; OVARIECTOMY; RABBITS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERUS;

EID: 0033963732     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.00919.x     Document Type: Article

References (41)

1. Bjarnason, K., Skrumsager, B.K. & Kiehr, B. (1997) Levormeloxifene, a new partial estrogen receptor agonist demonstrates antiresorptive and antiatherogenic properties in postmenopausal women. Journal of Bone Mineral Research, 12 (Suppl. 1), S346.
2. Bjarnason, N.H., Bjarnason, K., Haarbo, J., Rosenquist, C. & Christiansen, C. (1996) Tibolone: prevention of bone loss in late postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 81, 2419-2422.
3. Bjarnason, N.H., Bjarnason, K., Haarbo, J., Coelingh Bennink, H.J.T. & Christiansen, C. (1997a) Tibolone: influence on markers of cardiovascular disease. Journal of Clinical Endocrinology and Metabolism, 82, 1752-1756,
4. Bjarnason, N.H., Bjarnason, K., Hassager, C. & Christiansen, C. (1997b) The response in bone mass during Tibolone therapy is related to bone turnover in elderly women. Bone, 20, 151-155.
5. Bjarnason, N.H., Haarbo, J., Byrjalsen, I., Kauffman, R.F. & Christiansen, C. (1997c) Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation, 96, 1964-1969.
6. Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Williams, D.C., Cullinan, G.J., Bendele, R., Kauffman, R.F., Bensch, W.R., Frolik, C.A., Termine, J.D. & Bryant, H.U. (1994) Raloxifene (LY 139481HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigations, 93, 63-69.
7. Bryant, H.U., Kauffman, R.F., Iversen, P., Cox, D.A., Mitlak, B.H. & Heath, H.I.I.I. (1998) Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. Authors response by Clarkson, T.B. & Anthony, M.S. Journal of Clinical Endocrinology and Metabolism, 83, 3001-3004.
8. Bush, T.L., Fried, L.P. & Barrett-Connor, E. (1988) Cholesterol, lipoproteins and coronary heart disease in women. Clinical Chemistry, 34, B60-B70.
9. Clarkson, T.B., Anthony, M.S. & Jerome, C.P. (1998) Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. Journal of Clinical Endocrinology and Metabolism, 83, 721-726.
10. Colditz, G.A. (1998) Relationship between estrogenlevels, use of hormone replacement therapy and breast cancer Journal of the National Cancer Institute, 90, 814-823.
11. Costantino, J.P., Kuller, L.H., Ives, D.G., Fisher, B. & Dignam, J. (1997) Coronary heart disease mortality and adjuvant tamoxifen therapy. Journal of the National Cancer Institute, 89, 776-782.
12. Cummings, S.R., Eckert, S., Krueger, K., Grady, D., Powles, T., Cauley, J.A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M., Lippman, M.E., Black, D., Glusman, J.E., Costa, A. & Jordan, V.C. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. Journal of the American Medical Association, 281, 2189-2197.
13. Delmas, P.D., Bjarnason, N.H., Mitlak, B.H., Ravoux, A.-C., Shah, A.S., Huster, W.J., Draper, M.W. & Christiansen, C. (1997) The effects of raloxifene on bone mineral density, serum cholesterol and uterine endometrium in postmenopausal women. New England Journal of Medicine, 337, 1641-1647.
14. Ettinger, B., Black, D.M., Mitlak, B.H., Knickerbocker, R.H., Nickelsen, T., Genant, H.K., Christiansen, C., Delmas, P.D., Zanchetta J.R., Stakkestad, J., Glüer, C.G., Krueger, K., Cohen, F.J., Eckert, S., Ensrud, K.E., Avioli, L.V., Lips, P., Cummings, S.R., for the Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. Journal of the American Medical Association, 282, 637-645.
15. Geiser, J., Ni, L., Knadler, M.P., Henry, D., Dere, W. & Allerheiligen, S. (1998) The population pharmacokinetics of raloxifene in postmenopausal women. Pharmaceutical Science, 1 (Suppl. 1), 518.
16. Grodstein, F., Stampfer, M.J., Colditz, G.A., Willett, W.C., Manson, J.E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S.E., Hunter, D.J., Hennekens, C.H. & Speizer, F.E. (1997) Postmenopausal hormone therapy and mortality. New England Journal of Medicine, 336, 1769-1775.
17. Grodstein, F., Stampfer, M.J., Manson, J.E., Colditz, G.A., Willett, W.C., Rosner, B., Speizer, F.E. & Hennekens, C.H. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine, 335, 453-461.
18. Haarbo, J. & Christiansen, C. (1996) The impact of female sex hormones on secondary prevention of atherosclerosis in ovariectomized, cholesterol-fed rabbits. Atherosclerosis, 123, 139-144.
19. Haarbo, J., Leth-Espensen, P., Stender, S. & Christiansen, C. (1991) Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Journal of Clinical Investigations, 87, 1274-1279.
20. Henriksson, P., Stamberger, M., Eriksson, M., Rudling, M., Diczfalusy, U., Berglund, L. & Angelin, B. (1989) Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterol-fed rabbit. European Journal of Clinical Investigations, 19, 395-403.
21. Holm, P., Korsgaard, N., Shalmi, M., Andersen, H.L., Hougaard, P., Skouby, S.O. & Stender, S. (1997a) Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. Journal of Clinical Investigations, 100, 821-828.
22. Holm, P., Shalmi, M., Korsgaard, N., Guldhammer, B., Skouby, S.O. & Stender, S. (1997b) A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arteriosclerosis Thrombosisis and Vascular Biology, 17, 2264-2272.
23. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., for the HERS Research Group. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association, 280, 605-613.
24. Kaplan, H.M. & Timmons, E.H. (1979) In: The Rabbit. A Model for the Principles of Mammalian Physiology and Surgery, pp. 127-12. Academic Press, Inc., New York.
25. Kauffman, R.F., Bensch, W.R., Roudebusch, R.E., Cole, H.W., Bean, J.S., Phillips, D.L., Monroe, A., Cullinan, G.J., Glasebrook, A.L. & Bryant, H.U. (1997) Hypocholesterolemic activity of raloxifene: pharmacological characterization as a selective estrogen receptor modulator. Journal of Pharmacological and Experimental Therapy, 280, 146-153.
26. Kauffman, R.F. & Bryant, H.U. (1995) Selective estrogen receptor modulators. Drug News and Perspectives, 8, 531-539.
27. Kicovic, P.M., Cortes-Prieto, J., Luisi, M., Milojevic, S. & Franchi, F. (1982) Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction, 6, 81-91.
28. Kushwawa, R.S., Lewis, D.S., Carey, K.D. & McGill, H.C. (1991) Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.). Arteriosclerosis and Thrombosis, 11, 23-31.
29. Lufkin, E.G., Wahner, H.W., O'Fallon, W.M., Hodgson, S.F., Kotowicz, M.A., Lane, A.W., Judd, H.L., Caplan, R.H. & Riggs, B.L. (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Annals of Internal Medicine, 117, 1-9.
30. Marslew, U., Riis, B. & Christiansen, C. (1991) Progestogens: therapeutic and adverse effects in early postmenopausal women. Maturitas, 13, 7-16.
31. McDonald, C.C., Alexander, F.E., Whyte, B.W., Forrest, A.P. & Stewart, H.J. (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. British Medical Journal, 11, 977-980.
32. Paganini-Hill, A. (1996) Oestrogen replacement therapy and Alzheimer's disease. British Journal of Obstetrics and Gynaecology, 103(Suppl. 13), 80-86.
33. Ravnikar, V.A. (1992) Compliance with hormone replacement therapy: are women receiving the full impact of hormome replacement therapy preventive health benefits? Womens Health Issues, 2, 75-80; 80-82.
34. Stampfer, M.J. & Colditz, G.A. (1991) Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Preventitive Medicine, 20, 47-63.
35. Sulistiyani, Adelman, S.J., Chandrasekaran, A., Jayo, J. & St. Clair, R.W. (1995) Effect of 17α-dihydroequilin sulfate, a conjugated equine estrogen and ethynylestradiol on atherosclerosis in cholesterol-fed rabbits. Arteriosclerosis Thrombosis and Vascular Biology, 15, 837-846.
36. Thompson, S.G., Kienast, J., Pyke, S.D.M., Haverkate, F. & Loo, J.C.W. (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New England Journal of Medicine, 332, 635-641.
37. Wagner, J.D., Clarkson, T.B., St Clair, R.W., Schwenke, D.C., Shively, C.A. & Adams, M.R. (1991) Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. Journal of Clinical Investigations, 88, 1995-2002.
38. Walsh, B.W., Kuller, L.H., Paul, S., Farmer, M., Lawrence, J.B., Shah, A.S. & Anderson, P.W. (1998) The effect of raloxifen on serum lipids and coagulation factors in healthy, postmenopausal women. Journal of the American Medical Association, 279, 1445-1451.
39. Williams, J.K., Wagner, J.D., Li, Z., Golden, D.L. & Adams, M.R. (1997) Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arteriosclerosis Thrombosis and Vascular Biology, 17, 403-408.
40. Wilson, P.W., Garrison, R.J. & Castelli, W.P. (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. New England Journal of Medicine, 313, 1038-1043.
41. Zandberg, P., Smit, M.J., Peters, J.L.M., de Reeder, E., Dernacker, P.N.M. & Meuleman, D.G. (1998) Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arteriosclerosis Thrombosis and Vascular Biology, 18, 1844-1854.